Copy
December/2020
View this email in your browser
Twitter
Facebook
Website
Instagram
YouTube
Email
 

Welcome to the January newsletter!
And a happy new year.

What a year it was, let's all take a deep breath and embrace 2021 with open yet socially distanced arms. The Australian Psychedelic Society hopes that in this time you have been able to reflect on what you need in your life and use that intention to power yourself into what might be a glorious 2021. 
This issue we have important news regarding the rescheduling of Kambo and Nitros oxide, as well as some exciting research into DMT getting the go-ahead, and don't forget to check out the artwork from our psychedelic community. 
As always, we thank our community for continuing to adapt and adhere to the restrictions at events with ease over this past year and we are excited to bring our psychedelic communities more content, events and advocacy in 2021. This February will see the APS committee meeting for a strategy day (likely online at this stage) to plan the APS's trajectory for the coming years. If you would like to contribute or would like to be involved with volunteering with the APS in 2021, contact us via email (Links above) or our social media channels. 
The Australian Psychedelic society committee and volunteers wish everyone a content and safe 2021!

 

Find your local Psychedelic Group here
On Christmas Eve 2020, the Therapeutic Goods Administration (TGA) announced a number of proposed scheduling amendments to how nitrous oxide and Kambo/Sapo are classified. Nitrous oxide would be reclassified as Schedule 10 (Substances of such danger to health as to warrant prohibition of sale, supply and use) except for medical use, or when supplied in containers of greater than 50cm³ or 10g. Kambo would be classified as Schedule 9 (Prohibited Substance) - no exceptions. The Australian Psychedelic Society is still formulating a response but is concerned at the potential for the harm that could occur due to these changes. The TGA is taking submissions on these proposals until the close of business 27 January 2021.
Click Here to read more on the TGA website

Have you subscribed to the Australian Psychedelic Society on Youtube?

Our channel has explored many exciting topics over the years; from 'Bad Trips' with James Jesso to talks with Dr Marg Ross about the therapeutic potential of psychedelic-assisted psychotherapy for the terminally ill to screenings and panels for award-winning films such as From Shock to Awe, Dosed and A trip of Compassion. While we are not sure which events we will be able to hold and collaborate on as 2021 unfolds, we will do our best to provide fun and engaging content.

Visit the APS Website for Articles from our Psychedelic Community

Visit Australian Psychedelic Society Blog

Psychedelic Drug DMT To Undergo First Clinical Trial To Treat Depression

A London based neuropharmacological company, Small Pharma, has received regulatory approval in the United Kingdom to undertake the world's first clinical trials using N,N-dimethyltryptamine (DMT) in human patients to treat depression. DMT is a short-lasting (20 minutes at a maximum) psychedelic drug which has long garnered respect, love, and fear from the psychedelic community due to its powerful effects. Some argue it is the most intense of the classic psychedelics, by weight, it is dwarfed in potency by LSD, which is psychoactive in the micrograms. Due to this, DMT users can take tremendously high doses of the drug and return to relative sobriety rapidly. The standard experienced intensity of a DMT trip is as high as it is, not because it is more powerful, per se, but rather because the average dose aimed for can be far greater than is consumed with other, longer-lasting psychedelics. The rapidness of its effects and additional difficulty in integrating such an experience, or receiving therapy throughout the experience, have left DMT's antidepressant effects under-researched compared to LSD and psilocybin. Although, if anecdotal reports are anything to go by, there may be great therapeutic potential in the molecule and its effectiveness may be bolstered, rather than diminished, by its short duration of action. Small Pharma is working in collaboration with Imperial College London's Centre for Psychedelic Research and has received Phase I/IIa approval, aiming to test the compound in healthy volunteers and patients suffering from major depressive disorder.

Canadian Health Care Professionals Can Now Legally Consume Psychedelic Mushrooms


National health regulators Health Canada have recently granted exemptions to several health care professionals so that they may possess and consume psilocybin mushrooms, according to CBC News and a recent announcement by Canadian Minister of Health Patty Hajdu. The office can grant certain exemptions from certain federal laws against controlled substances. The move comes in response to a request from therapists to be legally allowed to consume psilocybin themselves so that they can have a direct experience of the experiential and therapeutic effects of the drug. As the office has been granting requests by certain patients in severe circumstances to undergo psilocybin assisted psychotherapy, the therapists argued that it was necessary that they too should experience the drug to understand how to best work with the medicine and incorporate it into the therapeutic process. A strong driver behind the process is the Canada-based non-profit TheraPsil, which advocates for increased acceptance of and access to psilocybin therapy.
 

Enpsychedelia Radio Show and Podcast
 
Play catch up over the holidays!
New episodes and content coming for 2021! Watch this space. 

Find latest podcasts here. http://wp.enpsychedelia.org/
 

Fiona submitted this delightful artwork earlier in the year. Fiona and her art can be found @spirityou on Instagram.
"This year I entered into the realm of psychedelics and it's utterly changed my life. My drawing is based on my oyster mushrooms I grow at home but hopefully is able to speak broadly of mushrooms and the magic they all possess!" 

We will be developing Psychedelic creatives as a feature of our psychedelic communities, if you'd like to express your interest in taking part in Psychedelic Creatives please email  Antanika at adelaide@psychedelicsociety.org.au. 
Twitter
Facebook
Website
Instagram
YouTube
Email
 
 
Copyright © 2019 Australian Psychedelic Society, All rights reserved. 
We are the Australian Psychedelic Society. You are receiving this email because you've shown interest in knowing what we're doing. 

Our mailing address is: 
Australian Psychedelic Society
PO Box 464
Brunswick VIC 3056
Australia


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

 






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Australian Psychedelic Society · 20/1 Manna Gum Ct · Coburg, Vic 3058 · Australia